RxDoctor Payments Data

Aviva Iofel, MD

Internal Medicine · Los Angeles, CANPI 1619918182

Payments from drug & device makers

$1,072in general payments, 2019–2025

Across 54 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$409
  • Amgen$161
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$135
  • Novo Nordisk$80
  • Arbor Pharmaceuticals, Inc.$60
  • AstraZeneca$53
  • plus $174 from 7 others

What the payments were for

  • Food & beverage$1,06199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,072 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$120,479
Medicare patients
285
Services billed
1,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate206$225,605
CreonLipase/Protease/Amylase301$224,498
OzempicSemaglutide187$172,266
Diclofenac Epolamine275$169,216
LinzessLinaclotide241$140,893
JanumetSitagliptin Phos/Metformin Hcl216$140,395
DapagliflozinDapagliflozin Propanediol149$91,566
Metformin Er GastricMetformin Hcl63$86,776
Dexlansoprazole DrDexlansoprazole403$80,758
FarxigaDapagliflozin Propanediol95$62,979
EliquisApixaban83$51,823
XareltoRivaroxaban89$49,611
Diclofenac Sodium147$45,530
JardianceEmpagliflozin51$40,607
Icosapent Ethyl251$40,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$409$365,391542 claims
Novo NordiskOzempic, Rybelsus$80$187,424201 claims
MerckJanumet, Januvia$19$164,429259 claims
AstraZenecaFarxiga, Nexium$53$74,183137 claims
Lilly USA, LLCMounjaro, Trulicity$46$66,89967 claims
PfizerEliquis$14$51,82383 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$60$27,756102 claims
AmgenProlia$161$22,28713 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$135$20,56238 claims
Sumitomo Pharma America, Inc.Gemtesa$27$20,19144 claims
GSKAnoro Ellipta$19$16,07631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →